These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23773069)

  • 21. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
    Fabbro S; Schaller K; Seeds NW
    J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alzheimer's disease, amyloid peptide and synaptic dysfunction].
    Hémar A; Mulle C
    Med Sci (Paris); 2011; 27(8-9):733-6. PubMed ID: 21880261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.
    Wilcock DM; Schmitt FA; Head E
    Biochim Biophys Acta; 2016 May; 1862(5):909-14. PubMed ID: 26593849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
    Badhwar A; Brown R; Stanimirovic DB; Haqqani AS; Hamel E
    J Cereb Blood Flow Metab; 2017 Mar; 37(3):1120-1136. PubMed ID: 27339263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of impaired cerebral circulation on Alzheimer's disease pathology: evidence from animal studies.
    Villarreal AE; Barron R; Rao KS; Britton GB
    J Alzheimers Dis; 2014; 42(3):707-22. PubMed ID: 24927711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. beta-Amyloid formation as a potential therapeutic target for Alzheimer's disease.
    Cordell B
    Annu Rev Pharmacol Toxicol; 1994; 34():69-89. PubMed ID: 8042857
    [No Abstract]   [Full Text] [Related]  

  • 28. Blood will out: vascular contributions to Alzheimer's disease.
    Strickland S
    J Clin Invest; 2018 Feb; 128(2):556-563. PubMed ID: 29388925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.
    Klohs J; Rudin M; Shimshek DR; Beckmann N
    Front Aging Neurosci; 2014; 6():32. PubMed ID: 24659966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurovascular function in Alzheimer's disease patients and experimental models.
    Nicolakakis N; Hamel E
    J Cereb Blood Flow Metab; 2011 Jun; 31(6):1354-70. PubMed ID: 21468088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spectrum of vascular disease in dementia. From ischaemia to amyloid angiopathy.
    Weller RO; Preston SD
    Adv Exp Med Biol; 2001; 487():111-22. PubMed ID: 11403152
    [No Abstract]   [Full Text] [Related]  

  • 32. Alzheimer's amyloid hypothesis gains support.
    Butcher J
    Lancet; 2000 Dec 23-30; 356(9248):2161. PubMed ID: 11191550
    [No Abstract]   [Full Text] [Related]  

  • 33. Exploring the Therapeutic Potential of Protein Tyrosine Phosphatase 1B in hAPP-J20 Mouse Model of Alzheimer's Disease.
    Ghalayini J
    J Neurosci; 2020 Aug; 40(32):6100-6102. PubMed ID: 32759187
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel beta-amyloid aggregate inhibitors for Alzheimer's disease.
    Wong RMS; Li HW; Kwong DWJ; Yung KKL; Ke Y
    Hong Kong Med J; 2019 Aug; 25 Suppl 5(4):26-29. PubMed ID: 31416983
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis.
    Oprisiu R; Serot JM; Godefroy O; Black SE; Fournier A
    Lancet Neurol; 2006 Dec; 5(12):1001-2; author reply 1002-3. PubMed ID: 17110279
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis.
    Fullwood NJ; Hayashi Y; Allsop D
    Lancet Neurol; 2006 Dec; 5(12):1000-1; author reply 1002-3. PubMed ID: 17110278
    [No Abstract]   [Full Text] [Related]  

  • 37. HDL from an Alzheimer's disease perspective.
    Button EB; Robert J; Caffrey TM; Fan J; Zhao W; Wellington CL
    Curr Opin Lipidol; 2019 Jun; 30(3):224-234. PubMed ID: 30946049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal models of Alzheimer's disease and drug development.
    Laurijssens B; Aujard F; Rahman A
    Drug Discov Today Technol; 2013 Sep; 10(3):e319-27. PubMed ID: 24050129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracting β-amyloid from Alzheimer's disease.
    Dries DR; Yu G; Herz J
    Proc Natl Acad Sci U S A; 2012 Feb; 109(9):3199-200. PubMed ID: 22328154
    [No Abstract]   [Full Text] [Related]  

  • 40. Impaired occipital cerebrovascular reactivity as a biomarker for vascular β-amyloid.
    Schreiber S; DiFrancesco JC
    Neurology; 2020 Sep; 95(10):415-416. PubMed ID: 32641536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.